Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes (Q44620317)

4 December 2017

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes (English)

1 reference

4 December 2017

1 reference

1 reference

Ted Okerson

1

1 reference

4 December 2017

Ping Yan

series ordinal

2

1 reference

4 December 2017

Anthony Stonehouse

series ordinal

3

1 reference

4 December 2017

Robert Brodows

series ordinal

4

1 reference

4 December 2017

17 December 2009

1 reference

Journal of Clinical Hypertension

4 December 2017

1 reference

4 December 2017

23

1 reference

4 December 2017

334-339

1 reference

4 December 2017

3

1 reference

Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study.

4 December 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Characteristic patterns of circadian variation in plasma catecholamine levels, blood pressure and heart rate variability in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

Treatment and control of blood pressure in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

7 January 2021

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

7 January 2021

Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

7 January 2021

Exenatide use in the management of metabolic syndrome: a retrospective database study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

7 January 2021

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.245

7 January 2021

Identifiers

DOI

10.1038/AJH.2009.245

1 reference

4 December 2017

1 reference